期刊
CURRENT OPINION IN CHEMICAL BIOLOGY
卷 17, 期 3, 页码 385-392出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2013.03.029
关键词
-
The immune system, and in particular T cells, can be harnessed to treat cancer. Several bispecific T cell engaging antibodies of the BiTE (R) format are in early or late-stage clinical development. These small recombinant antibody constructs effectively trigger killing of cancer cells by temporarily attached, polyclonal T cells. Blinatunnomab, a CD19/CD3-bispecific BiTE (R) antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. Three additional BiTE antibodies directed against surface target antigen expressed on solid tumors are being evaluated in phase I clinical trials. Alternative approaches to direct polyclonal T cells to kill cancer cells are under intense investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据